MVA GOOD MORNING MEETING – Maximize your asset’s value using Real World Evidence
Medicon Valley Alliance and Iqvia are pleased to invite you to a Good morning meeting on the 28th of November in Copenhagen focusing on maximizing your asset’s value using Real World Evidence.
Regulators and payers are increasingly using real-world evidence (RWE) to support their decision-making. What does this mean for biotech companies and how can biotech leaders use RWE to design smarter clinical trials, shorten time to market, reduce risk and ultimately increase peak sales?
Topics will include:
• The value from RWE
• RWE through the product lifecycle
• Creating evidence-based TPPs (Target Product Profile)
• Using RWE for smarter clinical trials better
• Using external comparators effectively
Date: Monday 28th of November 2022
Time: 08:30 – 10:30 CET
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Auditorium
|8:30||Networking, registration and light breakfast|
David Munis Zepernick, Director, Member Engagement and Communication, Medicon Valley Alliance
|9:05||The value of real-world evidence through the product life cycle|
Dr. Christopher Ball, Asset Partner, IQVIA
|9:25||How to use external comparators to maximum effect|
Maria Morizet, Real World Business Development Lead, Nordics, IQVIA
|09:45||Q&A session |
|10:30||End of Good Morning Meeting|
| ||Dr Christopher Ball, MD MBA, Asset Partner, IQVIA|
Christopher is a biotech asset partner at IQVIA. He helps high-potential biotechs accelerate time to market, reduce risk and maximize peak sales by providing access to IQVIA’s evidence-based insights and tailored holistic solutions.
He has previously worked as CEO of a US commercial-stage biotech, a venture capital investor and in strategic marketing at Johnson and Johnson. He started his career as a medical doctor and is trained in internal medicine and clinical epidemiology.
Christopher holds a pathology degree from the University of Cambridge, a medical degree from the University of Oxford and an MBA from the Wharton School of Business, University of Pennsylvania. He has written an award-winning book on evidence-based medicine.
| || |
| ||Maria Morizet, Real World Business Development Lead, Nordics, IQVIA.|
Maria is Account Director at IQVIA and is helping Nordic biotech companies maximize their use of Real World Evidence and help anticipate evidence requirements all through the development cycle to market. Maria is based in IQVIA’s French office but is a Swedish native.
Maria has over 15 years of experience from the pharmaceutical industry having worked at companies like Galderma, Stallergenes-Greer and Roche, followed by more than 5 years in the real world data sector.
Maria holds a business degree from Växjö University, Sweden.
|In collaboration with|